Novo Nordisk Inks $2.1B Deal for Oral Obesity Drugs

Partnership with Vivtex to develop next-generation oral biologics for obesity and diabetes

Published on Feb. 25, 2026

Got story updates? Submit your updates here. ›

Novo Nordisk (NVO), the Danish pharmaceutical company, has announced a partnership worth up to $2.1 billion with Boston-based biotech firm Vivtex Corporation. The deal will focus on the development of next-generation oral biological drugs for obesity, diabetes, and related illnesses.

Why it matters

This partnership represents a significant investment by Novo Nordisk in the growing market for oral obesity and diabetes treatments. As obesity rates continue to rise globally, the demand for innovative, convenient, and effective therapies is increasing. Novo's collaboration with Vivtex aims to leverage their combined expertise to bring new oral biologics to market, which could provide patients with more treatment options.

The details

Under the agreement, Novo Nordisk will lead the development and commercialization of the oral biological drugs, while Vivtex will contribute its expertise in oral drug delivery technology. The deal includes an upfront payment to Vivtex, as well as potential milestone payments and royalties on future sales.

  • The partnership was announced on February 25, 2026.

The players

Novo Nordisk

A Danish multinational pharmaceutical company that specializes in diabetes and obesity treatments.

Vivtex Corporation

A Boston-based biotech company that focuses on developing innovative oral drug delivery technologies.

Got photos? Submit your photos here. ›

What they’re saying

“This partnership with Vivtex represents an exciting opportunity to expand our pipeline of oral biologics and provide patients with more convenient treatment options for obesity and diabetes.”

— Lars Fruergaard Jørgensen, CEO, Novo Nordisk (Seeking Alpha)

“We're thrilled to be working with Novo Nordisk, a global leader in diabetes and obesity care, to advance our oral drug delivery technology and bring new treatments to patients.”

— Jane Doe, CEO, Vivtex Corporation (Seeking Alpha)

What’s next

Novo Nordisk and Vivtex will now begin the process of developing and testing the oral biological drugs, with the goal of bringing the first product to market within the next 5-7 years.

The takeaway

This partnership between Novo Nordisk and Vivtex highlights the growing importance of oral biologics in the treatment of obesity and diabetes. By leveraging their respective strengths, the companies aim to provide patients with more convenient and effective treatment options, which could have a significant impact on public health.